

30 March 2026

2026 Annual General Meeting of Doctor Care Anywhere Group Plc

Doctor Care Anywhere Group Plc (ASX:DOC, “Doctor Care Anywhere” or “the Company”), encloses its Notice of Annual General Meeting (“AGM” or “Meeting”) of Securityholders, Proxy Form which will be distributed to holders of fully paid ordinary shares and CDI Voting Instruction Form which will be distributed to holders of CHESS Depository Interests (“CDIs”) over fully paid ordinary shares, on or about 27 March 2026 (“Notice”).

Annual General Meeting of Securityholders

Details of the Meeting are set out below:

Date	Tuesday, 28 April 2026
Time	7:00pm (AEST) (being Tuesday, 28 April 2026 at 10:00am (BST))
Venue	InvestorHub, Level 16, 452 Flinders Street, Melbourne, Victoria 3000
Virtual Link	https://meetnow.global/MZ6V2UA

Using a computer, tablet or smartphone, Securityholders and proxyholders will be required to login at the above link. Online registration will open from 6:30pm AEST on Tuesday, 28 April 2026 (being 9:30am BST on Tuesday, 28 April 2026).

For the purpose of this Notice, holders of fully paid ordinary shares in the Company (“Shareholders”) and holders of CDIs (“CDI Holders”) are together referred to as “Securityholders”.

Shareholders and proxyholders – To attend and participate in the Meeting online follow the instructions below:

1. Click on ‘Join Meeting Now’.
2. Select ‘I am a shareholder/proxyholder’.
3. Enter your SRN/HIN. Proxyholders will need to contact Computershare on +61 3 9415 4000 one hour prior to the Meeting to obtain their unique email invitation link.
4. Enter your postcode registered to your holding if you are an Australian Shareholder or proxyholder for an Australian Shareholder. If you are an overseas Shareholder or proxyholder for an overseas Shareholder, select the country of your registered holding from the drop-down list.
5. Accept the Terms and Conditions and click ‘Continue’.

You can view the Meeting live, ask questions verbally or via a live text facility and cast votes at the appropriate times while the Meeting is in progress.

CDI Holders – To attend and participate in the Meeting online follow the instructions below:

If you participate in the Meeting online as a CDI Holder (and have not been appointed by CHESS Depository Nominees Pty Limited (“CDN”) as CDN’s proxy in respect of your holding), you can log in to the Meeting as follows:

1. Click on ‘Join Meeting Now’.
2. Select “I am a guest”.
3. Enter your name and email address.

Note that CDI Holders cannot vote online at the Meeting unless they have nominated themselves to be appointed as CDN’s proxy prior to the Meeting.

For personal use only

CDI Holders can view the Meeting live and can ask questions orally or via a live text facility at the appropriate times while the Meeting is in progress.

In accordance with ASX Listing Rule 3.17, the following documents are attached to this Notice:

1. Letter to Securityholders;
2. Notice of Meeting;
3. Proxy Form;
4. CDI Voting Instruction Form; and
5. Explanatory Memorandum.

Shareholders are encouraged to complete the Proxy Form and CDI Holders are encouraged to complete the CDI Voting Instruction Form and submit the applicable form as soon as possible prior to the Meeting as per the instructions circulated to Securityholders with the enclosed Notice.

The Company's 2025 Annual Report will be available via the Doctor Care Anywhere Investor Hub at <https://investors.doctorcareanywhere.com/> and on the ASX website.

This ASX release has been authorised for release by the Board of Directors.

– ENDS –

About Doctor Care Anywhere

Doctor Care Anywhere Group Plc is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways on its proprietary platform. DOC utilises its relationships with health insurers, healthcare providers and corporate customers to connect with patients to deliver a range of telehealth services.

Further Information

Computershare Company Secretarial Services Limited

Company Secretary

doctorcareanywherergroup-cosec@computershare.co.uk

Share Registry

Computershare Investor Services Pty Limited

GPO Box 242

Melbourne Victoria 3001

Australia

Enquiries (outside Australia) +61 3 9415 4000

Enquiries (within Australia) 1300 850 505

For personal use only

Letter to Securityholders

27 March 2026

2026 Annual General Meeting of Doctor Care Anywhere Group Plc

Dear Doctor Care Anywhere Securityholder,

The Annual General Meeting (“AGM” or “Meeting”) of Doctor Care Anywhere Group Plc (ASX:DOC, “Doctor Care Anywhere” or the “Company”) will be held on Tuesday, 28 April 2026 at 7:00pm (AEST) (being Tuesday, 28 April 2026 at 10:00am (BST)).

The Board and Executive Team are wholly UK-based. Accordingly, our 2026 AGM will be conducted as a hybrid meeting, whereby Securityholders can attend either in person at the offices of InvestorHub, Level 16, 452 Flinders Street, Melbourne, Victoria, 3000 or via the online platform provided by Computershare, our share registry (“Share Registry”) at <https://meetnow.global/MZ6V2UA>. The timing of the Meeting, whilst not ideal, is necessitated by the time zone differences between the UK and Australia where our Securityholders are primarily based.

We recognise the importance of you having the opportunity to communicate your views to us and value your participation so we have explained how this will work in the information provided with this Notice. This explains the business of the Meeting and provides voting information along with voting intention forms and how and where these can be lodged.

How you can participate virtually

The online platform will allow you to listen to the proceedings of the Meeting, ask questions of the Board and Shareholders will be able to vote in real time. You will need a desktop or mobile/tablet device with internet access, and you will need to provide your details (including SRN or HIN) in order to be verified as a Securityholder or proxyholder of the Company.

Alternatively, you can register as a visitor to the Meeting.

We recommend logging in to the online platform 10 minutes before the commencement of the Meeting using the instructions provided in this Notice.

Instructions for joining the Meeting will also be published on the Doctor Care Anywhere Investor Hub at <https://investors.doctorcareanywhere.com> prior to the Meeting. The webcast will also be archived on the Investor Hub for you to access at your convenience.

It should be noted that only Shareholders and holders of CDIs over fully paid ordinary shares (“CDI Holders”) who have nominated themselves to be appointed as CHES Depositary Nominees Pty Ltd’s (“CDN’s”) proxy prior to the Meeting may vote virtually at the Meeting.

Physical Attendance

For Securityholders attending the Meeting in person, we recommend arriving 20 minutes before the commencement of the Meeting to enable registration processes for both our host and Share Registry service to be completed. Registration opens from 6:30pm on Tuesday, 28 April 2026 (AEST) (being 9:30am on Tuesday, 28 April 2026 (BST)).

Securityholder questions

Although we will allow Securityholders to submit questions online during the Meeting, Securityholders are encouraged to submit questions, to the Company ahead of the Meeting and no later than 7:00pm on Wednesday, 22 April 2026 (AEST) (being 10:00am on Wednesday, 22 April 2026 (BST)). Please submit your advance questions by emailing doctorcareanywherogroup-cosec@computershare.co.uk. Further details are set out in the mail pack accompanying this Notice.

Securityholders will also be given a reasonable opportunity to ask questions related to the business of the Meeting, the Company’s operations or of the Auditor, at the end of the Meeting.

For personal use only

Should you have any questions regarding your security holding or the upcoming Meeting, please submit a question to our Share Registry on www.investorcentre.com/contact or contact the Share Registry on 1800 850 505 (within Australia) or +61 3 9415 4000 (outside Australia).

Appointing a Proxy

A Shareholder entitled to attend and vote at the Meeting may appoint a proxy to attend and vote at the Meeting on that Shareholder's behalf. The proxy need not be a member and can be an individual or company. If you wish to appoint a proxy, please complete and submit a Proxy Form (accompanying this Notice of Meeting) or contact the Share Registry on 1800 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) prior to the Meeting.

The completed Proxy Form needs to be received by the Company at the address shown on the form, by no later than 7:00pm AEST (10:00am BST) on Friday, 24 April 2026 in order for it to be valid.


CDI Holders must vote prior to the Meeting

Please note that CDI Holders will not be able to vote online during the Meeting but will be able to ask questions and will be able to submit a CDI Voting Instruction Form ahead of the Meeting.

CDI Holders can indicate their voting preferences to CHESS Depository Nominees Pty Limited ("CDN") in advance of the Meeting by completing the CDI Voting Instruction Form attached to this Notice and provide specific instructions on how their vote is to be exercised on each item of business. CDN must follow your instructions. The CDI Voting Instruction Form needs to be received at the address shown on the form not less than 96 hours (excluding Saturdays, Sundays and holidays) before the time fixed for the Meeting, being no later than 7:00pm AEST (10:00am BST) on Wednesday, 22 April 2026.

I look forward to welcoming you to our AGM.

Yours faithfully,



John Stier Chair

27 March 2026

For personal use only

Notice of Annual General Meeting of Securityholders

Notice is given that the Annual General Meeting of the Securityholders of Doctor Care Anywhere Group Plc (ASX:DOC, "Doctor Care Anywhere" or "the Company") will be held by way of a hybrid meeting on **Tuesday, 28 April 2026 commencing at 7:00pm (AEST) (being Tuesday, 28 April 2026 at 10:00am (BST))** at InvestorHub, Level 16, 452 Flinders Street, Melbourne, Victoria, 3000 and virtually at <https://meetnow.global/MZ6V2UA> ("AGM" or "Meeting"). Physical attendees are encouraged to arrive at least 20 minutes before the commencement of the Meeting to enable registration processes for both our host and registry service to be completed.

If attending the Meeting virtually, Securityholders will be able to participate, ask questions and Shareholders will be able to cast their vote whilst the Meeting is in progress via the online platform. Shareholders may also cast their vote ahead of the Meeting by completing and returning their Proxy Form in accordance with the instructions provided.

CDI Holders will not be able to vote virtually at the Meeting. CDI Holders are instead strongly encouraged to cast their vote by completing and returning the enclosed CDI Voting Instruction Form prior to the Meeting in accordance with the instructions provided to ensure their votes are counted.

All resolutions to be considered at the Meeting will be decided by a poll based on proxy votes received prior to the Meeting and votes cast during the Meeting.

For Securityholders wishing to attend virtually, further information on how to participate and vote during the Meeting via the online platform is set out in the virtual meeting guide appended to this Notice.

Closing Date for Director Nominations

The closing date for the receipt of nominations from persons wishing to be considered for election as a director is Monday, 20 April 2026 at the Company registered office, being 7 clear days before the AGM, pursuant to Article 79 of the Company's Articles of Association.

The Explanatory Memorandum appended to this Notice provides information on the matters to be considered at the Meeting. The Explanatory Memorandum, Proxy Form and CDI Voting Instruction Form are part of this Notice.

Notes:

1. To be entitled to vote, a Shareholder must first have their name entered in the Company's register of members by 7:00pm on Friday, 24 April 2026 (AEST) (being 10:00am on Friday, 24 April 2026 (BST)), or, if this Meeting is adjourned, at the close of business on the day which is two days prior to the date of the adjourned meeting. Changes to entries on the register of members after that time shall be disregarded in determining the rights of any member to participate and vote at the Meeting.
2. Members who have queries about the Meeting should email doctorcareanywherogroup-cosec@computershare.co.uk or submit a question to Computershare on www.investorcentre.com/contact. If you have a meeting day query, you can also contact the Share Registry standard phone lines (noted on voting intention form) by calling their standard phone number on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia)

Business of the Meeting

Set out below are the items of business that will be considered at the Meeting:

Ordinary Business

1. Financial Report and Accounts for the Year Ended 31 December 2025

“To receive the Director’s Report, Financial Report, Remuneration Report and Auditors’ Report for the Company and its wholly owned subsidiaries for the year ended 31 December 2025.”

Note: There is no requirement for Securityholders to approve the reports.

2. Resolution 1 – Approval of the Remuneration Report

To consider and, if thought fit, to pass the following item as an ordinary resolution:

“That the Directors’ Remuneration Report (including the statement by the Chair of the Remuneration Committee), for the financial year ended 31 December 2025 be received and approved.”

Board Recommendation and Chair’s Voting Intention for Resolution 1

The vote on this Resolution 1 is advisory only and does not bind the Directors of the Company. However, the Board will take the outcome of the vote into account in setting a remuneration policy for further years.

Directors will abstain, in the interests of good corporate governance, from making a recommendation in relation to this Resolution 1.

3. Resolution 2 – Re-appointment of Crowe LLP as Auditors

To consider, and if thought fit, to pass the following item as an ordinary resolution:

“That Crowe LLP be re-appointed as Auditors of the Company, to hold office until the conclusion of the next general meeting at which the accounts are laid before the Securityholders, and to authorise the Directors to determine the Auditor’s remuneration.”

Board Recommendation and Chair’s Voting Intention for Resolution 2

The Directors recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 2.

4. Resolution 3 – Re-election of David Jeremy Ravech as a Director

To consider and, if thought fit, to pass the following item as an ordinary resolution:

“That David Jeremy Ravech, who retires by rotation in accordance with Article 80 of the Company’s Articles and ASX Listing Rule 14.4 at this Annual General Meeting, and being eligible and offering himself for re-election, be re-elected as a Director of the Company.”

Board Recommendation and Chair’s Voting Intention for Resolution 3

The Directors (David Jeremy Ravech abstaining) recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 3.

5. Resolution 4 – Approval of the Grant of Options Laura O’Riordan

To consider and, if thought fit, to pass the following item as an ordinary resolution:

“That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to grant nil cost share options under the Doctor Care Anywhere Long Term Incentive Plan (“LTIP”) to Laura O’Riordan (or her nominee) on the terms and in the manner described in the Explanatory Memorandum.”

Board Recommendation and Chair’s Voting Intention for Resolution 4

The Directors (Laura O’Riordan abstaining) recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 4.

Note: A voting exclusion statement applies to this Resolution 4 (see the Voting Notes for details).

6. Resolution 5 – Approval of the Grant of Options to Matthew Addison

To consider and, if thought fit, to pass the following item as an ordinary resolution:

“ That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is hereby given for the grant of 2,500,000 share options under the Doctor Care Anywhere Long Term Incentive Plan (“LTIP”) to Matthew Addison on the terms and in the manner described in the Explanatory Memorandum.”

Board Recommendation and Chair’s Voting Intention for Resolution 5

The Directors (Matthew Addison abstaining) recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 5.

Note: A voting exclusion statement applies to this Resolution 5 (see the Voting Notes for details).

7. Resolution 6 – Authority to Allot Shares

To consider and, if thought fit, to pass the following item as an ordinary resolution:

“That the Directors be generally and unconditionally authorised for the purpose of section 551 of the UK Companies Act 2006 (the “Companies Act”) to exercise all the powers of the Company to:

- (A) allot Shares in the Company and grant rights to subscribe for, or to convert any security into, Shares in the Company up to an aggregate nominal amount of A\$6,843,989 (representing 122,214,082 CDIs, which represents approximately one-third of the Company’s issued CDIs (excluding treasury shares) as at 16 March 2026, being the latest practicable date prior to publication of this Notice); and*
- (B) allot equity securities (within the meaning of section 560(1) of the Companies Act) up to a further aggregate nominal amount of A\$6,843,989 (representing 122,214,082 CDIs, which represents approximately one-third of the Company’s issued CDIs (excluding treasury shares) as at 16 March 2026, being the latest practicable date prior to publication of this Notice), such authority to be used only in connection with a rights issue or open offer to Securityholders in proportion (as nearly as may be practicable) to their existing holdings, subject to such exclusions or other arrangements as the Directors may deem necessary or expedient to deal with treasury shares, fractional entitlements, or legal or practical problems under the laws of any overseas territory or the requirements of any regulatory body or stock exchange or any other matter,*

provided that in both cases:

- (i) this authority shall expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, 15 months after the passing of this Resolution; and*
- (ii) the Company may before such expiry make an offer or agreement which would or might*

require Shares or equity securities to be allotted or such rights to be granted after such expiry, and the Directors may allot Shares or equity securities or grant such rights in pursuance of such offer or agreement notwithstanding that the authority conferred by this Resolution has expired.

All unexercised authorities previously granted to the Directors to allot Shares or equity securities or to grant rights to subscribe for or to convert any security into Shares are hereby revoked."

Board Recommendation and Chair's Voting Intention for Resolution 6

The Directors recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 6.

Special Business

8. Resolution 7 – Approval of Additional 10% Placement Capacity – ASX Listing Rule 7.1A

To consider and, if thought fit, pass the following resolution as a special resolution:

"That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue, or agree to issue, Equity Securities up to 10% of the number of CDIs representing fully paid ordinary securities on issue at the time of issue, such number being calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Memorandum."

Board Recommendation and Chair's Voting Intention for Resolution 7

The Directors recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 7.

9. Resolution 8 – Disapplication of Pre-Emption Rights (15% Standard Placement Capacity – ASX Listing Rule 7.1)

To consider and, if thought fit, to pass the following item as a special resolution:

"That, subject to the passing of Resolution 6 (Authority to Allot Shares), the Directors be and are hereby empowered, pursuant to sections 570 and 573 of the Companies Act, to allot equity securities (as defined in section 560(1) of the Companies Act) for cash pursuant to the authority conferred by that Resolution and/or to sell ordinary shares held by the Company as treasury shares for cash, in each case as if section 561 of the Companies Act did not apply to any such allotment or sale, such power to be limited to:

- (A) the allotment of equity securities and/or sale of treasury shares (for cash in connection with an offer of, or invitation to apply for, equity securities open for acceptance for a fixed period, to Securityholders in proportion (as nearly as may be practicable) to their existing holdings (but subject to such exclusions or other arrangements as the Directors may deem necessary or expedient to deal with treasury shares, fractional entitlements, record dates, or legal, regulatory or practical problems in, or under the laws of, any territory or any other matter); and*
- (B) otherwise than pursuant to paragraph (A) above, the allotment of equity securities and/or sale of treasury shares for cash up to an aggregate nominal amount of A\$3,079,797 (representing 54,996,337 CDIs, which represents approximately 15% of the Company's issued CDIs (excluding treasury shares) as at 16 March 2026, being the latest practicable date prior to publication of this Notice),*

provided that this authority shall expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, 15 months from the date of passing of this Resolution, save that the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted (or treasury shares to be sold) after such expiry and the Directors may allot equity securities (or sell treasury shares) in pursuance of any such offer or agreement as if the power conferred by this Resolution had not expired."

Board Recommendation and Chair's Voting Intention for Resolution 8

The Directors recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 8.

10. Resolution 9 – Disapplication of Pre-Emption Rights (Additional 10% Placement Capacity – ASX Listing Rule 7.1A)

To consider and, if thought fit, to pass the following item as a special resolution:

“That, subject to the passing of Resolution 6 (Authority to Allot Shares) and in addition to any authority granted under Resolution 7 (Disapplication of Pre-Emption Rights – 15% Standard Placement Capacity – ASX Listing Rule 7.1)), the Directors be and are hereby empowered, pursuant to sections 570 and 573 of the Companies Act, to allot equity securities (as defined in section 560(1) of the Companies Act) for cash pursuant to the authority conferred by Resolution 6, and/or to sell ordinary shares held by the Company as treasury shares for cash, in each case as if section 561 of the Companies Act did not apply to any such allotment or sale.

Such power shall be limited to the allotment of equity securities and/or sale of treasury shares for cash up to an aggregate nominal amount of A\$2,053,199 (representing 36,664,224 CDIs, which represents approximately 10% of the Company's issued CDIs (excluding treasury shares) as at 16 March 2026, being the latest practicable date prior to publication of this Notice).

This authority shall expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, 15 months from the date of passing of this Resolution, save that the Company may before such expiry make an offer or agreement which would or might require equity securities to be allotted (or treasury shares to be sold) after such expiry, and the Directors may allot equity securities (or sell treasury shares) in pursuance of any such offer or agreement as if this authority had not expired.”

Board Recommendation and Chair's Voting Intention for Resolution 9

The Directors recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 9.

11. Resolution 10 – Authority to Purchase Own Shares

To consider and, if thought fit, to pass the following item as a special resolution:

“That, in accordance with the Companies Act, the Company be generally and unconditionally authorised for the purposes of section 701 of the Companies Act to make one or more market purchases (as defined in section 693(4) of the Companies Act) of Shares (which are represented as CDIs on the ASX) in the capital of the Company, provided that:

- (A) the maximum aggregate number of Shares authorised to be purchased is 36,664,224 CDIs (representing approximately 10% of the Company's issued CDIs (excluding treasury shares) as at 16 March 2026, being the latest practicable date prior to publication of this Notice);*
- (B) the minimum price which may be paid for each CDI is A\$0.056 (being the nominal value of the Share which is represented by a CDI), exclusive of expenses;*
- (C) the maximum price which may be paid for each CDI, exclusive of expenses, is the higher of:
 - (i) an amount equal to 5% above the average market value of a Share as derived from the Australian Securities Exchange's official trading records for the five business days immediately preceding the day on which the Share is contracted to be purchased; and*
 - (ii) the higher of the price of the last independent trade and the highest current independent bid on the trading venue where the purchase is carried out;**
- (D) unless previously renewed, varied or revoked, the authority hereby conferred shall expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, 15 months from the*

date of passing of this Resolution; and

- (E) the Company may make a contract or contracts to purchase Shares under the authority conferred by this Resolution prior to the expiry of such authority which will or may be executed wholly or partly after the expiry of such authority, and may make purchases of Shares in pursuance of any such contract or contracts as if the authority had not expired."*

Board Recommendation and Chair's Voting Intention for Resolution 10

The Directors recommend that all eligible voting Securityholders vote in favour of this Resolution. It is the intention of the Chair to vote undirected proxies in favour of this Resolution 10.

For personal use only

Explanatory Memorandum

This Explanatory Memorandum is to be read in conjunction with, and forms part of, the accompanying Notice.

Purpose

The purpose of this Explanatory Memorandum is to provide Securityholders with an explanation of the business of the Meeting and the resolutions to be proposed and considered at the Meeting to be held on Tuesday, 28 April 2026 at 7:00pm (AEST) (being Tuesday, 28 April 2026 at 10:00am (BST)) and to allow Securityholders to determine how they wish to vote on those resolutions.

Securityholders should read the Notice and this Explanatory Memorandum in full before deciding how to vote.

Capitalised Terms

Capitalised terms used in this Explanatory Memorandum have the meanings given to them in the Glossary, unless otherwise defined.

Ordinary Business

1. Financial Report and Accounts for the Year Ended 31 December 2025

Section 437 of the Companies Act requires the Company's Annual Report (comprised of the Director's Report, Financial Report, Remuneration Report and Auditors' Report) to be laid before the members in general meeting.

Securityholders are not required to vote on the Annual Report.

The Chair will give Securityholders a reasonable opportunity to ask questions and make comments on the management of the Company. Securityholders will also be given a reasonable opportunity to ask the Auditor questions about the conduct of the audit and the content of the Auditor's Report.

The Annual Report can be viewed on the Doctor Care Anywhere website:
<https://investors.doctorcareanywhere.com>.

2. Resolution 1 – Approval of the Remuneration Report

The Company has elected to prepare and submit a 2025 Remuneration Report to Securityholders. The section of the Remuneration Report that deals with the remuneration of directors and key management personnel of the Company will be put to a vote of securityholders for adoption by way of an advisory vote.

An advisory vote will not bind the Company or its Directors. However, the Board will take the outcome of the vote into consideration when reviewing the Company's future remuneration policies and practices.

The Remuneration Report is included within the Company's Annual Report which is available on the Company's website at the following link: <https://investors.doctorcareanywhere.com> and the Company's ASX announcement platform at www.asx.com.au.

The Chair intends to exercise all available proxies in favour of this Resolution 1.

Proxy Voting Restrictions

Proxy	Directions given	No directions given
Key Management Personnel	Vote as directed	Unable to vote
Chair	Vote as directed	Able to vote at discretion of Proxy
Other	Vote as directed	Able to vote at discretion of Proxy

For personal use only

3. Resolution 2 – Appointment of Crowe LLP as Auditors

Under the Companies Act, the Company is required at each general meeting at which financial statements are laid to appoint auditors who will remain in office until the next general meeting at which the financial statements are laid. Crowe LLP were appointed as the Company's auditors at the previous AGM held on 30 April 2025 and have expressed their willingness to continue in office.

In accordance with the Companies Act, Securityholders are also asked to authorise the Directors to determine the Auditors' remuneration.

The Directors support the appointment of Crowe LLP as Auditors and recommend that Securityholders vote in favour of this Resolution.

The Chair intends to exercise all available proxies in favour of this Resolution 2.

4. Resolution 3 – Re-election of David Jeremy Ravech as Director

Article 80.1 of the Company's Articles and ASX Listing Rule 14.4 provide that a Director must retire from office at the third Annual General Meeting since the Annual General Meeting at which they were last elected or re-elected, but shall be eligible for re-election. David was the co-founder of Synergix Health Limited, now Doctor Care Anywhere Group Plc. He served as executive Chairman of Synergix Health until November 2018. He was elected as a Director at the Company's Annual General Meeting in March 2023. David Jeremy Ravech retires and, being eligible, offers himself for re-election.

David was the co-founder of Synergix Health Limited, now Doctor Care Anywhere Group Plc. He served as executive Chairman of Synergix Health until November 2018.

For more than 20 years, David has led and invested in disruptive technology companies. Prior to his involvement with Doctor Care Anywhere, David was the founder and CEO of Overland Health (now part of Slater and Gordon Solutions), a technology-driven provider of rehabilitation services. He also founded, as director and later as Co-CEO, Global Freight Exchange which provided the world's leading airlines and freight forwarders with the first online price and availability comparison engine and transaction system for airfreight (with the company being sold in 2007 to Descartes (Nasdaq: DSGX), a provider of cloud-based logistics and supply chain management solutions).

The Chair intends to exercise all available proxies in favour of this Resolution 3.

5. Resolutions 4 & 5 – Grant of Options to Laura O'Riordan and Matthew Addison

Resolutions 4 and 5 seek Securityholder approval for the grant of share options to Laura O'Riordan, Director and Chief Executive Officer, and Matthew Addison, Non-Executive Director, under Doctor Care Anywhere's LTIP, pursuant to ASX Listing Rule 10.14 (together, "Director Options")

The Company has established the LTIP, which was approved by Securityholders at the Company's AGM on 29 April 2024, to provide equity-based incentives to align the interests of eligible participants, including the Company's Directors, with those of Securityholders, over the long term. Listing Rule 10.14 requires Securityholder approval for the issue of equity securities to Directors under an employee incentive scheme.

Each of Ms O'Riordan and Mr Addison is a Director of the Company and therefore falls within the scope of Listing Rule 10.14.1.

CEO Grant

The CEO Grant is proposed in connection with the remuneration arrangements for Laura O'Riordan. The Board considers the grant to be appropriate recognition of her contribution to the Company and to provide alignment between her interests and those of Securityholders over the long term. Under Ms O'Riordan's remuneration arrangements, her target annual bonus is 120% of base salary, of which 60% is payable in cash and 40% is delivered in nil cost share options under the LTIP. The CEO Options (the subject of Resolution 4) represent the equity component of Ms O'Riordan's FY2025 annual bonus, with an intended value of £104,923.

The CEO Options will be granted as soon as practicable after the 2026 AGM and in any event no later than three years after the date of the Meeting.

Grant Basis and Illustrative Information (Indicative only)

The information below is provided to assist Securityholders to understand the basis on which the CEO Grant has been determined, including how the number of CEO Options will be calculated.

Calculation of the Number of CEO Options

The number of CEO Options to be granted to Ms O’Riordan will be calculated on the date of grant by reference to the £104,923 equity value and the market price of the Company’s CDIs, as follows:

- Determine the volume weighted average price of the Company’s CDIs traded on the ASX over the twenty (20) trading days immediately preceding the grant date, expressed in A\$ (“**VWAP**”).
- Convert the VWAP into £ using the A\$/£ spot exchange rate on the grant date published by WM/Refinitiv (“**FX Rate**”).
- Divide £104,923 by the VWAP (converted into £), and round the resulting figure down to the nearest whole Option.

Accordingly:

- Number of CEO Options = $\text{£}104,923 \div (\text{20-day VWAP in A\$} \times \text{FX Rate})$ (rounded down to the nearest whole CEO Option).
- By way of illustration only, based on a 20-day VWAP proxy of A\$0.16 as at 16 March 2026 and an A\$/£ exchange rate of A\$1.00:£0.53, this would result in approximately 1,237,299 CEO Options. The actual number of CEO Options granted will be calculated by reference to the VWAP and A\$/£ exchange rate prevailing at the time of grant and may therefore differ from this indicative figure.

The actual value (if any) that may be realised by Ms O’Riordan will depend on the future CDI price performance and the satisfaction of vesting conditions.

NED Grant

Prior to his appointment as a Non-Executive Director in October 2024, Matthew Addison had acted as an independent consultant to the Company in late 2023. At that time, the Board had agreed that Mr Addison would be remunerated by way of share options issued under the terms of the Company’s LTIP. Share options were used as they align the consultant’s remuneration with shareholder value and reflect the milestone-based nature of the consultancy engagement; the options replace cash fees and are only exercisable on achievement of specified financial milestones. Securityholder approval for the grant of these share options was provided at an Extraordinary General Meeting held on 4 January 2024. As part of the granted option tranches, Mr Addison held 2,500,000 options with an exercise price of A\$0.125, which were due to lapse on 31 December 2025. Mr Addison had requested an extension to the exercise period on the basis that he had been unable to exercise the options. In his current capacity as Non-Executive Director, Mr Addison receives a director’s fee of £50,000 per annum.

The Board noted, following external legal advice, that the ASX Listing Rules prohibit any variation to the terms of options that would extend the exercise period unless a waiver is granted by ASX. The Board determined that seeking such a waiver would not be appropriate in the circumstances.

Having regard to its duties under section 172 of the Companies Act 2006, including its duty to act in the way most likely to promote the success of the Company for the benefit of its members as a whole, and having considered the valuable contribution made by Mr Addison to the Company and the value of his expertise, the Board resolved that the most appropriate course of action was to allow the options to lapse and to propose a new grant of options for Securityholder approval at the 2026 AGM.

The actual value (if any) that may be realised will depend on the future CDI price performance and whether and when the Options are exercised. The Company has attributed a fair value to the 2,500,000 Options with an exercise price of A\$0.125 by applying a standard option-pricing methodology commonly used for valuing equity-based remuneration. The valuation takes into account inputs including the Company’s prevailing share price at the valuation date, expected share price volatility, the remaining term of the Options and the applicable risk-free interest rate.

Grant Information

For the purposes of Listing Rules 10.14 and 10.15, the following information is provided in relation to each of the proposed Director Options. Key terms are summarised in Attachment A to this Notice.

Term	Laura O’Riordan	Matthew Addison
Maximum number of Options that may be granted	To be determined in accordance with the formula described above (being £104,923 divided by the 20-day VWAP of the Company’s CDIs immediately preceding the grant date, converted to GBP using the A\$/£ spot exchange rate published by WM/Refinitiv on the grant date and rounded down to the nearest whole Option).	2,500,000
Maximum number of CDIs on exercise	Not fixed – determined by the formula described above.	2,500,000
Issue Price	Nil	Nil
Exercise Price	Nil	A\$0.125 per share
Vesting Conditions	50% after one year (30 April 2027) and the remaining 50% after year two (30 April 2028).	N/A – options have fully vested.
Expiry Date	No later than the tenth anniversary of the date of grant.	31 December 2026
Dilution %	To be determined once CEO Options are confirmed upon grant – applying the illustrative example of approximately 1,237,299 options described above results in a dilution of 0.34%.	0.68%
Securities previously issued under the LTIP with Securityholder approval under LR 10.14	30 million options approved by Securityholders at the AGM held on 30 April 2025 and subsequently granted on 29 May 2025 as a one-off award, which formed part of the remuneration package for Ms O’Riordan’s appointment as CEO	2,500,000 options granted on 4 January 2024 with an exercise price of A\$0.125, expiring 31 December 2025, approved by Securityholders at the EGM held on 4 January 2024.
Date of by which Options will be granted	As soon as practicable after the 2026 AGM and in any event no later than three years after the date of that meeting.	
Consideration payable	Nil on grant.	Nil on grant; exercise price as set out above.
Average acquisition price	Nil	Nil

For personal use only

Vesting Conditions for the Director Options

The Director Options will be offered subject to certain vesting conditions, being:

- Ms O’Riordan’s continued service with the Company; and
- in the event of a Change of Control or other relevant corporate event under the LTIP, the Board may (subject to the LTIP rules, applicable law and the Listing Rules) determine that Ms O’Riordan will be entitled to exercise such proportion of her Options as the Board may specify, provided that the proportion is not less than the Minimum Proportion. Any exercise must occur within the period specified by the Board under the LTIP, and Options not exercised within that period will lapse in accordance with the LTIP. Mr Addison has no unvested Options.

Any Director Options that do not vest by the applicable vesting date (or that otherwise lapse in accordance with the rules of the LTIP) will lapse.

The Company also notes the following:

- it will not apply to the ASX for official quotation of the Director Options under the LTIP;
- Securities issued pursuant to the exercise of the Director Options will rank equally with Securities then on issue;
- the Company has the flexibility to issue new Securities or to purchase Securities on market for allocation to Ms O’Riordan and Mr Addison on vesting and exercise of Director Options;
- any dealing in Securities is subject to the constraints of Australian insider trading laws and the Company’s Securities Trading Policy. Ms O’Riordan and Mr Addison are specifically prohibited from entering into arrangements which operate to limit the economic risk of holding the Director Options, or any Securities allocated on their exercise, during the vesting period;
- on exercise of any vested Director Options with a non-nil Exercise Price, the Company will receive cash equal to the applicable Exercise Price per Director Option multiplied by the number of Director Options exercised. The total amount of funds raised will depend on the number of Director Options that vest and are exercised and any cashless exercise or cash-settlement arrangements permitted under the LTIP rules. Any funds raised on exercise of the Director Options will be applied towards the Company’s working capital;
- no loan or financial assistance is provided in connection with the acquisition or exercise of the Director Options;
- details of any Director Options issued under the LTIP will be published in the Company’s Annual Report (including, where relevant, in the Remuneration Report) for the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14; and
- any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of securities under the LTIP after these Resolutions are approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14.

Effect of Passing Resolutions 4 and 5

No additional approval under Listing Rule 7.1 is required for the issue of the Director Options as approval is being sought under Listing Rule 10.14. If Securityholder approval is obtained for Resolutions 4 and 5, the issue of Director Options (and any CDIs issued on their exercise) will fall within exception 13 of Listing Rule 7.2 and will not reduce the Company’s capacity to issue equity securities without Securityholder approval under Listing Rule 7.1. If the Securityholder approval is not obtained for Resolutions 4 and 5, the Directors may elect to pay some or all of this benefit by way of a cash payment.

Voting Exclusion

A voting exclusion statement applies to these Resolutions (see the Voting Notes for details)

Directors Recommendation

The Directors of the Company (with the exception of Ms O’Riordan and Mr Addison) believe that this resolution is in the best interests of the Company and unanimously recommend that Securityholders vote in favour of this resolution.

The Chair intends to exercise all available proxies in favour of Resolutions 4 and 5.

6. Resolution 6 – Authority to Allot Shares

Resolution 6 seeks Securityholder approval for the Directors to be authorised to allot Shares in the capital of the Company.

Under section 551 of the Companies Act, the Directors are not permitted to allot Shares unless authorised to do so by Securityholders. Such authority can be granted either by the Company in general meeting or by the Articles of Association, and in both cases may only last for a maximum of five years.

Notwithstanding the statutory maximum, institutional best practice is to renew this authority annually. Accordingly, all unexercised previous authorities to allot are revoked by this new authority. This authority will expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, 15 months after the passing of this Resolution, except insofar as commitments to allot Shares have been entered into before that date.

In accordance with institutional guidelines, the Board considers it appropriate that the Directors be granted authority to allot Shares up to a maximum aggregate nominal amount of A\$13,687,977 representing 244,428,164 CDIs, which represents two-thirds of the Company's issued CDIs (excluding treasury shares) as at 16 March 2026 (being the latest practicable date prior to publication of this Notice). Of this amount, A\$6,843,989 representing 122,214,082 CDIs, which represents one-third of the Company's issued CDIs (excluding treasury shares) may only be allotted pursuant to a rights issue or other fully pre-emptive issue open to all Securityholders on the register on a fixed record date in proportion to their respective holdings. The Board has no present intention of exercising this authority.

Employee Share Schemes – Allotment and Pre-Emption Exemptions

Securityholders should note that the allotment authority sought under Resolution 6 does not extend to, and is not required for, allotments of Shares made to satisfy the exercise of options or the vesting of awards under the Company's employee share schemes, being the Doctor Care Anywhere Long-Term Incentive Plan ("LTIP"), Company Share Option Plan ("CSOP") and/or Save As You Earn ("SAYE") schemes.

This is because the Companies Act 2006 provides two relevant statutory exemptions in this context.

First, section 549(2) of the Act provides that the requirement for directors to obtain prior shareholder authorisation before allotting shares does not apply to allotments made in pursuance of an employees' share scheme. Accordingly, the Directors are not required to obtain, and are not relying on, the authority granted under Resolution 6 in order to allot Shares to satisfy exercises under the LTIP, CSOP, and/or SAYE.

Second, section 566 of the Act (as amended by the Companies Act 2006 (Allotment of Shares and Right of Pre-emption) (Amendment) Regulations 2009) provides that the statutory pre-emption rights conferred on existing Securityholders by section 561 of the Act do not apply to the allotment of equity securities that would, apart from any renunciation or assignment of the right to their allotment, be held under or allotted or transferred pursuant to an employees' share scheme. Accordingly, no disapplication of pre-emption rights is required in connection with allotments made to satisfy exercises or vestings under the LTIP, CSOP, and/or SAYE.

The LTIP, CSOP, and/or SAYE have been constituted as employees' share schemes within the meaning of section 1166 of the Act, being schemes for encouraging or facilitating the holding of shares by or for the benefit of bona fide employees or former employees of the Company and its subsidiaries. The Board has satisfied itself that both schemes qualify for the statutory exemptions described above.

The Chair intends to exercise all available proxies in favour of this Resolution 6.

Special Business

7. Resolution 7 – Approval of Additional 10% Placement Capacity – ASX Listing Rule 7.1A

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its securityholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period (**15% Capacity**).

Under Listing Rule 7.1A, however, an eligible entity can seek approval from its securityholders, by way of a special resolution passed at its annual general meeting, to increase this 15% Capacity limit by an extra 10% (**10% Placement Capacity**) during the 12-month period following the AGM (**7.1A Mandate**).

An eligible entity is one that, at the AGM date, has a market capitalisation of less than A\$300 million and is not included in the S&P/ASX 300 Index. The Company is, at the date of this Notice, an eligible entity for these purposes. If, on the date of the AGM, the Company is not an eligible entity, this Resolution will no longer be effective and will be withdrawn.

This Resolution seeks Securityholder approval by way of special resolution for the Company to benefit from the additional 10% capacity provided for under Listing Rule 7.1A to issue equity securities without further Securityholder approval.

If this Resolution is passed, the Company will be able to issue equity securities up to the combined 25% limit in Listing Rules 7.1 and 7.1A without any further Securityholder approval.

If this Resolution is not passed, the Company will not be able to access the additional 10% Placement Facility to issue equity securities without Securityholder approval provided for in LR 7.1A and will remain subject to the 15% limit on issuing equity securities without Securityholder approval set out in Listing Rule 7.1.

Existing quoted class and instrument

The Company's primary quoted security on ASX is CDIs, each representing one fully paid ordinary share in the Company. Any issue under the 7.1A Mandate will be in the Company's existing quoted CDI class.

Formula for Calculating the 10% Placement Facility – Listing Rule 7.1A.2

The maximum number of equity securities that may be issued by the Company under the 7.1A Mandate pursuant to Listing Rule 7.1A.2 is calculated in accordance with the following formula:

$$(A \times D) - E$$

where:

A = the number of ordinary securities on issue at the commencement of the "relevant period" (which, for the Company, is the 12-month period immediately preceding the date of the issue or agreement):

- plus the number of fully paid ordinary securities issued in the relevant period under an exception in Listing Rule 7.2, other than exception 9, 16 or 17;
- plus the number of fully paid ordinary securities issued in the relevant period on the conversion of convertible securities within rule 7.2 exception 9 where:
 - the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or
 - the issue of, or agreement to issue, the convertible securities was approved, or taken under the Listing Rules to have been approved, under rule 7.1 or rule 7.4;
- plus the number of fully paid ordinary securities issued in the relevant period under an agreement to issue securities within rule 7.2 exception 16 where:
 - the agreement was entered into before the commencement of the relevant period; or
 - the agreement or issue was approved, or taken under the Listing Rules to have been approved, under rule 7.1 or rule 7.4;

- plus the number of fully paid ordinary securities issued in the relevant period with approval of Securityholders under Listing Rules 7.1 or 7.4;
- plus the number of partly paid ordinary securities that became fully paid in the relevant period;
- less the number of fully paid ordinary securities cancelled in the relevant period.

D = 10%

E = the number of equity securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months before the date of the issue or agreement to issue that were not issued with the approval of Securityholders under Listing Rule 7.1 or 7.4.

The ability of an entity to issue equity securities under Listing Rule 7.1A is in addition to the entity's 15% Capacity under Listing Rule 7.1. The actual number of equity securities that the Company will have capacity to issue under Listing Rule 7.1A will be calculated immediately prior to the date of issue of the equity securities in accordance with the formula stated above.

Type and Number of Equity Securities

Any equity securities issued under the 7.1A Mandate must be in the same class as an existing class of equity securities quoted on the ASX. The Company, as at 16 March 2026, has on issue one class of quoted equity securities, being CDIs as follows:

ASX Security Code and Description	Total Number
DOC: CHES Depository Interests 1:1	366,642,246

Specific information required by Listing Rule 7.3A

Placement Period

The period for which the approval of the 7.1A Mandate will be valid (as set out in Listing Rule 7.1A.1) commences immediately following this Annual General Meeting and expires on the first to occur of the following:

- the date that is 12 months from the date of this Annual General Meeting, being 28 April 2027;
- the time and date of the Company's next Annual General Meeting; or
- the time and date of the approval by Securityholders of a transaction under Listing Rules 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking).

7.1A Mandate Period

The Company will only issue and allot the equity securities approved under the 7.1A Mandate during the 7.1A Mandate Period.

Minimum Issue Price and Cash Consideration – Listing Rule 7.1A.3

The equity securities will be issued at an issue price of not less than 75% of the Volume Weighted Average Price ("VWAP") for the Company's equity securities in an existing quote class, calculated over the 15 trading days on which trades in that class were recorded immediately before:

- the date on which the price at which the equity securities are to be issued is agreed by the Company and the recipient of the securities; or
- if the equity securities are not issued within 10 trading days of the date in paragraph (a) above, the date on which the equity securities are issued.

Securities can only be issued for cash consideration under the 7.1A Mandate.

Purpose of the Funds Raised

Funds raised under any issue under the 7.1A Mandate may be:

- growth initiatives (including acquisitions or investments);

- balance sheet flexibility and/or general working capital.

Risk of Economic and Voting Dilution

If this resolution is approved by Securityholders and the Company issues equity securities under the 7.1A Mandate, the existing Securityholders' voting power in the Company will be diluted as shown in the dilution table below.

Securityholders may be exposed to economic risk and voting dilution, including the following:

- the market price for the Company's equity securities may be significantly lower on the date of the issue of the equity securities than on the date of this Annual General Meeting; and
- the equity securities may be issued at a price that is at a discount to the market price for the Company's equity securities on the issue date,
which may have an effect on the amount of funds raised by the issue of the equity securities.

The dilution table shows the hypothetical dilution of existing Securityholders on the basis of the market price of CDIs as at 16 March 2026 (**Current CDI Price**) and the current number of CDIs for variable "A" calculated in accordance with the formula in Listing Rule 7.1A.2 as at the date of this Notice of Meeting.

The dilution table also shows:

- two examples where variable "A" has increased by 50% and 100%. Variable "A" is based on the number of CDIs the Company has on issue. The number of CDIs on issue may increase as a result of issues of CDIs that do not require Securityholder approval (for example, a pro-rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Securityholders' meeting; and
- two examples of where the issue price of CDIs has decreased by 50% and increased by 100% as against the current market price.

This dilution table has been prepared on the following assumptions:

- the Company issues the maximum number of equity securities available under the 7.1A Mandate;
- no convertible security is exercised and converted into a CDI before the date of the issue of the Equity Securities;
- the 10% voting dilution reflects the aggregate percentage dilution against the issued capital at the time of issue. This is why the voting dilution is shown in each example as 10%.
- the table does not show an example of dilution that may be caused to a particular Securityholder by reason of placements under the 7.1A Mandate, based on that Securityholders' holding at the date of the Annual General Meeting.
- the table shows only the effect of issues of equity securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1.
- the issue of equity securities under the 7.1A Mandate consists only of CDIs.
- the Current CDI Price is \$0.140, being the closing price of the CDIs on ASX on 16 March 2026.

Table – Dilution Table

Variable 'A' in Listing Rule 7.1A.2	Dilution Scenario	Issue Price		
		50% decrease in Current CDI Price	Current CDI Price	100% increase in Current CDI Price
		\$0.070	0.140	0.28
Current Variable A 366,642,246 CDIs	10% Voting Dilution	36,664,224 CDIs		
	Funds raised	\$2,566,495.68	\$5,132,991.36	\$10,265,982.72
50% increase in current Variable A 549,963,369 CDIs	10% Voting Dilution	54,996,336 CDIs		
	Funds raised	\$3,849,743.52	\$7,699,487.04	\$15,398,974.08
100% increase in current Variable A 733,284,492 CDIs	10% Voting Dilution	73,328,449 CDIs		
	Funds raised	\$5,132,991.43	\$10,265,982.86	\$20,531,965.72

The number of CDIs issued under each scenario has been rounded down to the nearest whole CDI.

Allocation Policy

The allottees of any equity securities to be issued under the 7.1A Mandate have not yet been determined. However, the allottees of equity securities could consist of current Securityholders or new investors (or both), on of whom will be related parties of the Company. The Company will determine the allottees at the time of any issue under the 7.1A Mandate, having regard to the following factors:

- the purpose of the issue;
- alternative methods for raising funds available to the Company at the time, including but not limited to, an entitlement issue or other offer where existing Securityholders may participate;
- the effect of the issue of equity securities on the control of the Company;
- the circumstances of the Company, including, but not limited to, the financial position and solvency of the Company;
- prevailing market conditions;
- advice from corporate, financial and broking advisers (if applicable).

Any issue to a related party (or their associate) would be subject to separate Securityholder approval under Listing Rule 10.11, unless an exception applies.

Previous Issue under Listing Rule 7.1A.2

Information about equity securities issued under Listing Rule 7.1A.2 in the 12-month period preceding the date of the Meeting is set out as follows:

- the Company has not issued or agreed to issue any Equity Securities under Listing Rule 7.1A.2 in the 12-month period preceding the date of this Meeting.
- the Company had not agreed, before the 12-month period referred to in the preceding paragraph, to issue any Equity Securities under rule 7.1A.2 where such securities remain unissued as at the date of the Meeting.

Effect of Passing this Resolution

If Securityholders pass this resolution, the number of equity securities permitted to be issued under the 7.1A Mandate will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 set out in section 8; and the Company will be able to issue equity securities up to a combined 25% of the CDIs on issue without further Securityholder approval.

Special Resolution

The ability to issue equity securities under the 7.1A Mandate is subject to Securityholder approval by way of a special resolution. This means it requires approval of 75% of the votes cast by Securityholders present or represented, and eligible to vote.

Directors Recommendation

The Directors of the Company believe that this resolution is in the best interests of the Company and unanimously recommend that Securityholders vote in favour of this resolution.

The Chair intends to exercise all available proxies in favour of this Resolution 7.

Voting Exclusions

No voting exclusions apply to Resolution 7.

8. Resolution 8 – Disapplication of Pre-Emption Rights (15% Standard Placement Capacity – ASX Listing Rule 7.1); and

Resolution 9 – Disapplication of Pre-Emption Rights (Additional 10% – Listing Rule 7.1A)

These two resolutions together seek Securityholder approval to disapply the statutory pre-emption rights that apply to the Company under the Companies Act, in order to align the Company's UK statutory position with the full extent of its placement capacity under the ASX Listing Rules.

UK Statutory Context

Section 561 of the Companies Act requires that when a company registered in England and Wales proposes to allot equity securities for cash, it must first offer those securities to existing Securityholders in proportion to their existing holdings. These rights may only be disapplied by Securityholder resolution under section 570 of the Companies Act.

This obligation applies to the Company solely by virtue of its registration in England and Wales and is entirely separate from, and not affected by, the Company's listing on the ASX. The Pre-Emption Group's Statement of Principles (the "PEG Principles") – a voluntary code directed at companies listed on UK regulated markets – does not apply to the Company, as the Company's shares are listed solely on the ASX. The Board has therefore determined the level of disapplication authority to seek by reference to ASX market norms rather than the PEG Principles.

ASX Listing Rule 7.1 — 15% Standard Placement Capacity (Resolution 8)

Under ASX Listing Rule 7.1, ASX-listed entities have a standing capacity to issue equity securities representing up to 15% of their issued ordinary share capital in any 12-month period without prior Securityholder approval under Australian listing rules. Resolution 8 seeks a disapplication authority aligned precisely to this 15% capacity.

ASX Listing Rule 7.1A — Additional 10% Placement Capacity (Resolution 9)

ASX Listing Rule 7.1A provides eligible entities with an additional placement capacity of up to 10% of issued ordinary share capital, over and above the standard 15% capacity under Rule 7.1, in any 12-month rolling period. To be eligible to use this additional capacity, an entity must obtain Securityholder approval by special resolution at its AGM. This approval must be renewed annually.

The Company is an eligible entity for the purposes of ASX Listing Rule 7.1A. The Board considers it prudent to seek approval to utilise this additional capacity in order to preserve the Company's maximum operational and financial flexibility. Resolution 7 accordingly seeks Securityholder approval under ASX Listing Rule 7.1A, and a corresponding disapplication authority (through Resolution 9) under the Companies Act to ensure that the Company can deploy that additional capacity in compliance with both its ASX and UK legal obligations.

Combined Effect of Resolutions 8 and 9

If both resolutions are passed, the Company will hold disapplication authority covering up to 25% of its issued ordinary share capital in aggregate – being 15% under Resolution 6 (aligned to ASX Listing Rule 7.1) and a further 10% under Resolution 7 (aligned to ASX Listing Rule 7.1A). This reflects the maximum

placement capacity available to the Company under the ASX Listing Rules and ensures that both authorities can be deployed without triggering pre-emption requirements under the Companies Act.

The Board has no present intention of exercising either authority to the full extent, but considers it in the best interests of Securityholders to maintain the full range of flexibility consistent with the Company's funding requirements, strategic objectives, and the norms of the ASX market in which the Company's securities are traded.

Where the Company undertakes a placement utilising either authority, it is the Board's intention, where operationally and commercially practicable, to provide existing Securityholders with an opportunity to participate through a share purchase plan or other follow-on offer mechanism at the same or equivalent pricing, consistent with standard ASX market practice.

Both authorities will expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, 15 months after the passing of the relevant resolution.

The Chair intends to exercise all available proxies in favour of this Resolution 8 and 9.

9. Resolution 10 – Authority to Purchase Own Shares

Resolution 10 seeks Securityholder approval to authorise the Company to make market purchases of its own Shares, pursuant to section 701 of the Companies Act.

The authority being sought permits the Company to purchase up to a maximum of 36,664,224 CDIs (representing approximately 10% of the Company's issued CDIs (excluding treasury shares) as at 16 March 2026, being the latest practicable date prior to publication of this Notice). This is in line with standard institutional guidelines and current UK market practice.

The Board has no present intention of exercising this authority. However, the Board considers it appropriate to maintain this flexibility so that purchases may be made if, having regard to market conditions prevailing at the time, the Company's financial position, other investment opportunities, and the overall effect on Securityholders, they are considered to be in the best interests of the Company and Securityholders generally.

Any Shares purchased pursuant to this authority may either be cancelled, thereby reducing the number of Shares in issue, or held in treasury for potential re-issue at a later date, subject to the allotment authority in force at the time.

This authority will expire at the conclusion of the next Annual General Meeting of the Company or, if earlier, 15 months after the passing of this Resolution.

The Chair intends to exercise all available proxies in favour of this Resolution 10.

Voting Notes

Voting Exclusion Statements

Voting Exclusion - Resolution 4

The Company will disregard any votes cast in favour of Resolution 4 by or on behalf of:

- any person who is eligible to participate in the Company's LTIP;
- Ms Laura O'Riordan; or
- an associate of any of that person.

However, this does not apply to a vote cast in favour of a resolution by:

- a person as proxy or attorney for a person who is entitled to vote on the Resolution in accordance with directions given to the proxy or attorney to vote on the Resolution in that way;
- the Chairperson of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chairperson to vote on the Resolution as the Chairperson decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting Exclusion – Resolution 5

The Company will disregard any votes cast in favour of Resolution 5 by or on behalf of:

- any person who is eligible to participate in the Company's LTIP;
- Mr Matthew Addison; or
- an associate of any of that person.

However, this does not apply to a vote cast in favour of a resolution by:

- a person as proxy or attorney for a person who is entitled to vote on the Resolution in accordance with directions given to the proxy or attorney to vote on the Resolution in that way;
- the Chairperson of the meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chairperson to vote on the Resolution as the Chairperson decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Attachment A – LTIP

The LTIP has the following key terms:

Term	Description
Date	2 December 2020 (Reapproved by Securityholders at the Company's AGM held on 29 April 2024 and amended by the Board on 26 June 2024)
Eligibility	Options may be granted at the Company's discretion to employees of the Company and its subsidiaries.
Grant limit	None
Vesting	Vesting of the Options will occur upon satisfaction (or waiver, where permitted) of the vesting conditions provided in the terms and conditions of the Options. The vesting conditions are determined by the Board at the time of grant. Examples of vesting conditions include time-based conditions and performance-based conditions such as measurement of total shareholder returns against the Company's peers.
Types of awards	Options to acquire Shares and CDIs (on a one for one basis) (Option).
Exercise Price	The exercise price is set out in the terms of the grant of the individual Options. The exercise price may be nil.
Terms of the Options	The Board may determine the terms of the Options which may include the exercise price, expiry date, vesting conditions and other terms.
Exercise	An Option holder may only exercise the Option if, and to the extent that, any relevant vesting conditions have been satisfied.
Cessation of employment	<p>If the Option holder gives or receives notice of termination of employment, the Option holder cannot exercise an Option while the notice remains effective unless permitted by the Board.</p> <p>The LTIP contains good leaver and bad leaver provisions and defines the circumstances where a participant may be considered a good leaver or bad leaver. In these circumstances the Board may specify the proportion of the Option that a good leaver may exercise at the next exercise period and the period within which they can be exercised, with the balance lapsing.</p> <p>If the Option holder dies, the Option holder's personal representatives may exercise a proportion of the Option as the Board may specify for a period of 12 months following the Option holder's death.</p>
Change of control	If there is a change in control of the Company (e.g. where there is an offer for all of the Shares / CDIs or there is a negotiation of a sale agreement for a change of control the Option Holder will be entitled to exercise such proportion of their Options as the Board may specify (not being less than the proportion that has vested by reference to time-based or performance-based conditions at the date of the relevant event) during such period as the Board may specify. Options shall lapse, to the extent not exercised, on the expiry of the period specified by the Board.
New issues	An Option holder is not entitled to participate in any new issue of securities without first exercising any vested Options and receiving

For personal use only

	the Shares prior to the record date for the new issue.
Pro rata issues	If the Company makes a pro rata issue (except a bonus issue) of Shares / CDIs to existing holders of Shares / CDIs, and no Share / CDI has been issued in respect of an Option before the record date for determining entitlements to the pro rata issue, the exercise price of the Option will be reduced according to the formula specified in the ASX Listing Rules.
Bonus issues	If the Company makes a bonus issue of Shares / CDIs to existing holders of Shares / CDIs, and no Share / CDI has been issued in respect of an Option before the record date for determining entitlement to the bonus issue, then the number of underlying Shares / CDIs over which the Option is exercisable will be increased by the number of Shares / CDIs which the Option holder would have received if the Option holder had exercised the Option before the record date for the bonus issue. No adjustment will be made to the exercise price.
Transfer	An Option holder must not transfer or assign or have any charge or other security interest created over an Option (or any right arising under it), otherwise the Option will lapse.
Lapse	An Option will normally lapse on the earliest to occur of (amongst other things): the expiry date; the transfer of an Option; where an Option holder becomes bankrupt; or where an Option holder ceases to be an employee of the Company (see "Cessation of Employment" commentary above).
Reconstructions	If there is a reorganisation of the issued capital of the Company (including a consolidation, subdivision, reduction or return) then the rights of an Option holder (including the number of Shares and CDIs over which the Option is granted and the exercise price) will be changed to the extent necessary to comply with the ASX Listing Rules applying to a reorganisation of capital at the time of reorganisation.
Shares and CDIs	Shares and CDIs allotted and issued following the exercise of an Option, will rank equally with Shares and CDIs in issue at the date of allotment.
Administration	The Board administers the LTIP.
Governing law	The LTIP is governed by the laws of England and Wales.
Other terms	The LTIP contains customary and usual terms for dealing with administration, amendment, participation rights, notices and termination of any incentive plans.

Glossary

AGM means this Meeting.

Annual Report or **2025 Annual Report** means the Director's Report, Financial Report, Remuneration Report and Auditors' Report for the Company and its wholly owned subsidiaries for the year ended 31 December 2025.

Articles means the articles of association of the Company, as amended or superseded.

ASX means ASX Limited ABN 98 008 624 691 or the market operated by it, as the context requires.

ASX Corporate Governance Principles means the Corporate Governance Principles and Recommendations (4th edition) published by the ASX Corporate Governance Council in February 2019.

ASX Listing Rules mean the Listing Rules of ASX.

Auditor means Crowe LLP.

Auditor's Report means the Auditors' Report for the Company and its wholly owned subsidiaries for the year ended 31 December 2025.

Board or **Board of Directors** means the current board of directors of the Company.

CDI means a CHESS Depository Interest over an ordinary share in the capital of the Company.

CDI Holder means a registered holder of a CDI.

CDI Voting Instruction Form means the voting instruction form accompanying this Notice of Meeting.

CDN means the Securityholder of record for all Shares beneficially owned by holders of CDIs.

CEO Options means the Options proposed to be issued to Laura O'Riordan in accordance with Resolution 4.

Chair means the chair of the Meeting.

Companies Act means the *UK Companies Act 2006* (UK).

Company means Doctor Care Anywhere Group Plc ARBN 645 163 873.

Computershare means Computershare Investor Services Pty Limited ACN 078 279 277.

Corporations Act means the *Corporations Act 2001* (Cth).

CSOP means the Company Share Option Plan adopted on 15 April 2020 and last approved by Securityholders on 29 April 2024.

Directors means the current directors of the Company.

Explanatory Memorandum means the explanatory Memorandum accompanying this Notice of Meeting.

HIN means Holder Identification Number.

LTIP means the Long-Term Incentive Plan adopted on 2 December 2020 and last approved by Securityholders on 29 April 2024.

Meeting means the 2026 Annual General Meeting of the Company to be held on Tuesday, 28 April 2026 at 7:00pm AEST (being Tuesday, 28 April 2026 at 10:00am (BST)).

Notice or Notice of Meeting means this notice of meeting including the Explanatory Memorandum, the Proxy Form and the CDI Voting Instruction Form.

Proxy Form means the proxy form accompanying this Notice of Meeting.

Remuneration Report means the remuneration report of the Company contained in the Directors' Report.

SAYE means the Save As You Earn scheme last approved by Security holders on 29 April 2024.

Securityholder means a Shareholder and/or CDI Holder.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

SRN means a Shareholder Reference Number.

For personal use only



Doctor Care Anywhere Group PLC
(Company Number 08915336)
(ARBN 645 163 873)

Need assistance?



Phone:
1300 850 505 (within Australia)
+61 3 9415 4000 (outside Australia)



Online:
www.investorcentre.com/contact



YOUR VOTE IS IMPORTANT

For your vote to be effective it must be received by **7:00pm (AEST) or 10:00am (BST) Wednesday, 22 April 2026.**

CDI Voting Instruction Form

How to Vote on Items of Business

Each CHESS Depository Interest (CDI) is equivalent to one Ordinary share in the capital of the Company, so that every 1 (one) CDI registered in your name at 22 April 2026 entitles you to one vote.

You can vote by completing, signing and returning your CDI Voting Instruction Form. This form gives your voting instructions to CHESS Depository Nominees Pty Ltd, which will vote the underlying shares on your behalf. You need to return the form no later than the time and date shown above to give CHESS Depository Nominees Pty Ltd enough time to tabulate all CHESS Depository Interest votes and to vote on the underlying shares.

SIGNING INSTRUCTIONS FOR POSTAL FORMS

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the Australian registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Only duly authorised officer/s can sign on behalf of a company. Please sign in the boxes provided, which state the office held by the signatory, ie Sole Director, Sole Company Secretary or Director and Company Secretary. Delete titles as applicable.

Lodge your Form:

Online:

Lodge your vote online at www.investorvote.com.au using your secure access information or use your mobile device to scan the personalised QR code.

Your secure access information is

Control Number: 188674

SRN/HIN:

By Mail:

Computershare Investor Services Pty Limited
GPO Box 242
Melbourne VIC 3001
Australia

By Fax:

1800 783 447 within Australia or
+61 3 9473 2555 outside Australia



PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.

For personal use only

Change of address. If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with 'X') should advise your broker of any changes.

CDI Voting Instruction Form

Please mark to indicate your directions


STEP 1 CHESSE Depository Nominees Pty Ltd will vote as directed

Voting Instructions to CHESSE Depository Nominees Pty Ltd

I/We being a holder of CHESSE Depository Interests of Doctor Care Anywhere Group PLC hereby direct CHESSE Depository Nominees Pty Ltd to vote the shares underlying my/our holding at the Annual General Meeting of Doctor Care Anywhere Group PLC to be held at InvestorHub, Level 16, 452 Flinders Street, Melbourne, Victoria 3000 and virtually on Tuesday, 28 April 2026, 7:00pm (AEST) or 10:00am (BST) and at any adjournment or postponement of that meeting in accordance with the directions below.

By execution of this CDI Voting Form the undersigned hereby authorises CHESSE Depository Nominees Pty Ltd to appoint such proxies or their substitutes to vote in their discretion in accordance with the directions set out below. The Chair of the Meeting will vote all undirected proxies in favour of all Resolutions of the business.

STEP 2 Items of Business

 PLEASE NOTE: If you mark the **Abstain** box for an item, you are directing CHESSE Depository Nominees Pty Ltd or their appointed proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

For personal use only

		For	Against	Abstain
1	Approval of the Remuneration Report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	Re-appointment of Crowe LLP as Auditors	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Re-election of David Jeremy Ravech as a Director	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	Approval of the Grant of Options Laura O'Riordan	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	Approval of the Grant of Options to Matthew Addison	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	Authority to Allot Shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Approval of Additional 10% Placement Capacity – ASX Listing Rule 7.1A	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Disapplication of Pre-Emption Rights (15% Standard Placement Capacity – ASX Listing Rule 7.1)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Disapplication of Pre-Emption Rights (Additional 10% Placement Capacity – ASX Listing Rule 7.1A)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10	Authority to Purchase Own Shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

SIGN Signature of Securityholder(s) *This section must be completed.*

Individual or Securityholder 1

Sole Director and Sole Company Secretary

Securityholder 2

Director

Securityholder 3

Director/Company Secretary

Contact Name _____

Contact Daytime Telephone _____

Date ____ / ____ / ____